|   From the Trenches

Should I Stay Or Should I Go? Big Pharma Execs Taking The Biotech Plunge

That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive. You may have noticed that more and more seasoned pharma executives are making the move from big pharma or big biotech to lead small biotech companies. Read more.


  |   In the News

Atlas to split life sciences, tech businesses

Cambridge-based venture capital firm Atlas Venture will split, with its life sciences and technology franchises becoming separate companies. Read more.


  |   Press Release

Zafgen Announces Initiation of Phase 3 trial of Beloranib in Prader-Willi Syndrome

Zafgen today announced that it has initiated the first Phase 3 clinical trial, in the United States, with its lead product candidate, beloranib, in the treatment of Prader-Willi syndrome (PWS). PWS is a rare disease and the most common known genetic cause of life-threatening obesity. Read more.